Displaying drugs 14226 - 14250 of 14741 in total
Heparan-N-sulfatase (human, recombinant)
Recombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.
Investigational
HMI-203
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
Investigational
Autologous skin culture
Investigational
MUL001
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
LB-P8
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum).
Investigational
QXL138AM
QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.
Investigational
PVX-410 component XBP1 US184-192(YISPWILAV)
Investigational
PVX-410 component CD138 260-268(GLVGLIFAV)
Investigational
MB-107
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Investigational
B7-H3-specific chimeric antigen receptor T cells
Investigational
PBFT02
PBFT02 is a non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin.
Investigational
scAAV9.U7.ACCA
scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA. Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
CTX120
CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.
Investigational
CTX110
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
SLN500
SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA
Investigational
ALLO-715
ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).
Investigational
Displaying drugs 14226 - 14250 of 14741 in total